Pieper Steven 4
4 · Xeris Biopharma Holdings, Inc. · Filed Nov 26, 2024
Insider Transaction Report
Form 4
Pieper Steven
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-11-22$1.55/sh+19,483$30,199→ 1,441,820 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-22−16,843→ 0 totalExercise: $1.55Exp: 2027-02-04→ Common Stock (16,843 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-22−2,640→ 0 totalExercise: $1.55Exp: 2027-06-12→ Common Stock (2,640 underlying)
Footnotes (2)
- [F1]The reporting person received the stock options on February 7, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. The options vested in four equal installments on February 2018, 2019, 2021, and 2021.
- [F2]The reporting person received the stock options on June 12, 2017 pursuant to an award under the Company's 2011 Stock Option/Stock Issuance Plan. The options vested in four equal installments on June 2018, 2019, 2021, and 2021.